2950 - Dosimetric Factors Linked to Postoperative Pulmonary Complications and Intensive Care Unit Stay in Locally Advanced Esophageal Cancer Patients Undergoing Preoperative Chemoradiotherapy
2954 - Assessing Dose Response and Patterns of Failure in Patients with Node Negative Anal Squamous Cell Carcinoma
Location: Hall C
Presenter: Kara Banson, MD – NYU Langone Health- Radiation Oncology
12:45 PM - 2:00 PM ET
2955 - Phase IA/IB Study of OAR-Based, Dose-Escalated SBRT with Real Time Adaptive MRI Guidance for Liver Metastases: Preliminary Safety and Efficacy Results
2956 - Ablative Radiotherapy in Patients with Large Volume Liver Metastases and in Those with Prior Liver Directed Therapies: An Analysis of Safety and Local Control
2958 - Hypertension and Survival Outcomes after Radiotherapy in Esophageal Cancer
Location: Hall C
Presenter: Tyren Busby, BS – The Ohio State University Wexner Medical Center
12:45 PM - 2:00 PM ET
2959 - Feasibility Analysis of Omitting the Clinical Target Volume in Thoracic Radiotherapy for Locally Advanced Esophagus Cancer: A Propensity Score-Matched Cohort Study
2960 - Stereotactic Ablative Radiotherapy Combined with Fruquintinib and Tislelizumab in Metastatic Colorectal Cancer: Updated Findings from a Single-Arm, Prospective Phase II Trial (RIFLE)
Location: Hall C
Presenter: Yajie Chen, PhD – Fudan University Shanghai Cancer Center
12:45 PM - 2:00 PM ET
2961 - Short-Course Radiotherapy Combined with Chemotherapy and PD-1 Inhibitor in Proficient Mismatch Repair or Microsatellite Stable (pMMR/MSS) Low-Lying Early Rectal Cancer: Preliminary Findings from a Pro
Location: Hall C
Presenter: Yajie Chen, PhD – Fudan University Shanghai Cancer Center
12:45 PM - 2:00 PM ET
2962 - A Phase II Clinical Trial of Sintilimab Combined with Lower Dose Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
2963 - Novel Roles of HOXD11 and HOXD13 in Mediating Response to Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
Location: Hall C
Presenter: Zhenguo Shi, MD – Department of Radiation Oncology, Cancer Center, Zhongshan Hospital, Fudan University
12:45 PM - 2:00 PM ET
2964 - Combining Avelumab with Platinum/5-Fluorouracil and Radical Hypofractionated Radiotherapy for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma: A Phase II Prospective Trial
2973 - mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible
2977 - Safety of NBTXR3 Radioenhancer Delivery in Liver Metastases
Location: Hall C
Presenter: Benjin Facer, MD – James Cancer Center at Ohio State University
12:45 PM - 2:00 PM ET
2978 - A Phase II Clinical Trial of Radiotherapy Combined with Anlotinib in Locoregional Recurrent Esophageal Squamous Cell Carcinoma after Radical Surgery
Location: Hall C
Presenter: ChengCheng Fan, MD – The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
12:45 PM - 2:00 PM ET
2979 - Matched Cohort Analysis of Ultra-Hypofractionated Preoperative Radiation Therapy vs. Standard Fractionation for Soft Tissue Sarcoma
Location: Hall C
Presenter: Cong Fan, BS – Cleveland Clinic Lerner College of Medicine
12:45 PM - 2:00 PM ET
2980 - Clinical Outcomes of Chemoradiotherapy Using Volumetric Modulated Arc Therapy (VMAT) for Locally Advanced Esophageal Cancer: A Single Institute Experience
2982 - Neoadjuvant Radiation Practice Patterns in Resected Pancreatic Ductal Adenocarcinoma at Academic Cancer Centers Participating in the Canopy Cancer Collective Learning Health Network
2983 - Radiation Doses to Small Bowel, Sigmoid and Anal Canal during Preoperative Radiation for Locally Advanced Rectal Cancer: Do They Impact Long-Term Bowel Function?
Presenter: Beatriz Guevara, MS – University Hospitals Cleveland Medical Center
12:45 PM - 2:00 PM ET
2990 - Pattern of Primary Tumor Residual and Lymph Node Spread in Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy with or without Pembrolizumab
Location: Hall C
Presenter: Xuan Han, MD – Ruijin Hospital, Shanghai Jiaotong University School of Medicine
12:45 PM - 2:00 PM ET
2991 - Predicting Benefit of Elective Nodal Irradiation in Pancreatic Adenocarcinoma: A Supervised Machine Learning Approach
2993 - Analyzing the Changes of Inflammation-related Cytokines by Using Olink immunoassay during Treatment of SCRT Combined with ICI in Proficient Mismatch Repair locally advanced Rectal Cancer
Location: Hall C
Presenter: Nan Xiao, MD – Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
12:45 PM - 2:00 PM ET
2994 - Predictive Value of Post-Radiotherapy PET with or without MRI to Identify Residual Disease in Patients with Anal Squamous Cell Carcinoma
Location: Hall C
Presenter: Sylvia Choo, BA – University of South Florida College of Medicine
12:45 PM - 2:00 PM ET
2995 - MRI-Defined Moderate Radiation Dose-Escalation for Locally Advanced Pancreas Cancer: A Phase II Study
2998 - Modeling Radiosensitivity with Gene Interactions Improves the Prediction of Pathological Response to Neoadjuvant Concurrent Chemoradiation in Esophageal Squamous Cell Carcinoma
3001 - Efficacy and Safety of the Contrast Agent Gadoterate in the Context of MR-Guided Stereotactic Body Radiotherapy for Upper Abdominal Tumors: A Preliminary Investigation
Location: Hall C
Presenter: Wenheng Jiang – Shandong Cancer Hospital and Institute
12:45 PM - 2:00 PM ET
3002 - MR-Guided Radiotherapy vs. Cone-Beam CT-Guided Radiotherapy for Hepatocellular Carcinoma: A Propensity-Matched Analysis
Location: Hall C
Presenter: Wenheng Jiang – Shandong Cancer Hospital and Institute
12:45 PM - 2:00 PM ET
3003 - Neoadjuvant Tislelizumab Combined with Chemoradiotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Single-Arm Phase II Study and Exploration of Immunologic Features
3004 - Safety and Efficacy of Neoadjuvant Chemoradiotherapy with Concurrent Weekly Versus Tri-Weekly Cisplatin/Nab-Paclitaxel in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma
Location: Hall C
Presenter: Xuquan Jing – Shandong Cancer Hospital and Institute
12:45 PM - 2:00 PM ET
3005 - Patterns of Recurrence in High-Risk Gastric Cancer: Defining the Role of Postoperative Radiation
3007 - Observed Survival for Esophageal Cancer Patients Receiving High-Dose (>50Gy) vs. Low-Dose (=45.0 Gy) Radiation in Tri-Modality Therapy and Differences in Dose to Thoracic Organs at Risk (OAR)
3007 - Observed Survival for Esophageal Cancer Patients Receiving High-Dose (>50Gy) vs. Low-Dose (=45.0 Gy) Radiation in Tri-Modality Therapy and Differences in Dose to Thoracic Organs at Risk (OAR)
3009 - MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer (MRI-ENHANCE): A Phase I Dose-Escalation Trial for Locally Advanced Rectal Cancer
3011 - Phase II Randomized Study of Short Course Radiotherapy Based Total Neo-Adjuvant Therapy and Brachytherapy Boost with or without Chlorophyllin in Reducing the Incidence of Acute Toxicity in Advanced Re
3013 - Meta-Analysis of Prospective Randomized Controlled Trials Evaluating of External Beam Radiation vs. Transarterial Chemoembolization for Hepatocellular Carcinoma (HCC)
Location: Hall C
Presenter: Ryan Kuehnle, BS – University of Texas Health Science Center San Antonio
12:45 PM - 2:00 PM ET
3014 - Outcomes and Predictive Factors in Large Hepatocellular Carcinoma Managed with Image-Guided Hypo-Fractionated Radiotherapy
Location: Hall C
Presenter: Ritesh Kumar, MD – Rutgers Cancer Institute of New Jersey
12:45 PM - 2:00 PM ET
3015 - CBCT-Guided Online Adaptive Radiotherapy for Rectal Cancer: Initial Dosimetric and Clinical Experience
Location: Hall C
Presenter: Albert Lee, MD – Columbia University Irving Medical Center
12:45 PM - 2:00 PM ET
3016 - Rates of Hepatotoxicity Following Liver-Directed Ablative External Beam Radiotherapy and Transarterial Radioembolization for Hepatocellular Carcinoma
Location: Hall C
Presenter: Grace Lee, MD – Harvard Radiation Oncology Program
12:45 PM - 2:00 PM ET
3017 - Transarterial Chemoembolization plus Radiotherapy vs. Transarterial Chemoembolization Alone for Single Hepatocellular Carcinoma within BCLC Stage 0-A
Location: Hall C
Presenter: Hye In Lee, MD – Seoul National University Hospital
12:45 PM - 2:00 PM ET
3018 - Tracking the Invisible: Primary Analysis of Real-Time Image Guidance in Liver SBRT from the XXXX : XXXX Trial
3020 - Multi-Modality Machine Learning Prediction Model of Hematologic Toxicity in Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
Location: Hall C
Presenter: Bin Li, PhD – Sun Yat-Sen University Cancer Center
12:45 PM - 2:00 PM ET
3021 - Preoperative Short-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor Administration for Locally Advanced Rectal Cancer: The Initial Results of a Randomized Phase II/III Trial (STELLAR II
3025 - The Addition of Pembrolizumab to Neoadjuvant Chemoradiotherapy and the Risk of Developing Postoperative Anastomotic Leakage for ESCC: An Analysis from a Prospective Cohort
3026 - The Relationship between Effective Dose to Immune Cells and Vertebral Marrow Dose and Hematologic Toxicity in Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
Location: Hall C
Presenter: Zhenjiang Li, PhD – Shandong Cancer Hospital and Institute
12:45 PM - 2:00 PM ET
3028 - Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma (RICE): A Prospective, Single-Arm, Phase II Trial
Location: Hall C
Presenter: Lin Lin, MD – Shanghai Chest Hospital Shanghai Jiao Tong University
12:45 PM - 2:00 PM ET
3029 - First-Line Low-Dose Radiotherapy with Immunochemotherapy Followed by Conventionally Fractionated Radiotherapy and Immunotherapy in Metastatic Esophageal Squamous Cell Carcinoma: A Phase Ib Trial
Location: Hall C
Presenter: Lin Lin, MD – Shanghai Chest Hospital Shanghai Jiao Tong University
12:45 PM - 2:00 PM ET
3030 - Preliminary Study on Biology-Guided Radiotherapy Planning for Metastatic Liver Lesions Using a Novel O-Ring PET Linac Platform
Location: Hall C
Presenter: An Liu, PhD – City of Hope National Medical Center
12:45 PM - 2:00 PM ET
3031 - Assessing Tumor Regression Grade Accuracy via MRI in Rectal Cancer Patients Following Neoadjuvant Chemoradiotherapy: Impact on Clinical Complete Remission Rate
Location: Hall C
Presenter: Guoqing Liu, MD, MS – University of Electronic Science and Technology
12:45 PM - 2:00 PM ET
3032 - Tumor Immune Microenvironment Remodeling and Prognosis of Patients with Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemotherapy with and without Immunotherapy
3033 - Comparative Analysis of Matching Accuracy and Dose Discrepancies: Bone vs. Fiducial Alignment in Free-Breathing Ablative Pancreatic Cancer Radiotherapy
Location: Hall C
Presenter: Yilin Liu, PhD – Memorial Sloan Kettering Cancer Center
12:45 PM - 2:00 PM ET
3034 - Neoadjuvant Immunotherapy Combined with Chemoradiation in Esophageal Cancer: An Individual Patient Data Meta-Analysis
Location: Hall C
Presenter: Yunsong Liu, MD – National Cancer Center/National Clinical Research Center for Cancer Cancer Hospital, CAMS & PUMC
12:45 PM - 2:00 PM ET
3035 - Sintilimab Combined with Definitive Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Single-Arm, Multicenter, Phase 2 Trial
3045 - Radiotherapy for Adolescents and Young Adults with Ewing Sarcoma and Rhabdomyosarcoma Compared to Children
Location: Hall C
Presenter: Karin Meijer, MSc – Amsterdam University Medical Center (AUMC)
12:45 PM - 2:00 PM ET
3046 - Short Course Radiotherapy with Simultaneous Integrated Boost in the Treatment of Rectal Cancer: Clinical and Pathological Response Rates
Location: Hall C
Presenter: Michael Melton, MD – University of Alabama Birmingham Hospital
12:45 PM - 2:00 PM ET
3047 - A Comparative Study on the Determination of Gross Tumor Volume for Hepatocellular Carcinoma Radiotherapy based on Multi-Phase Contrast-Enhanced Magnetic Resonance Imaging
3052 - Neoadjuvant Short-Course Radiotherapy Followed by Chemotherapy for Rectal Adenocarcinoma: Analysis of Clinical and Pathological Responses of Patients Treated in a Brazilian Tertiary General Hospital
3053 - Comparison of External Beam Radiation Modalities (Photon vs. Proton vs. Carbon Ion) in the Treatment of Hepatocellular Carcinoma: A Network Metanalysis
3056 - Predicting Pathological Lymph Node Involvement Using Machine Learning in Locally Advanced Rectal Cancer Patients Treated with Neoadjuvant Chemo-Radiotherapy
3059 - Disparities in Diagnosis and Access to Care in Patients with Young-Onset Colorectal Cancers in Northeast Ohio
Location: Hall C
Presenter: Rohan Patel, MD – UH Seidman Cancer Center Case Western Reserve University
12:45 PM - 2:00 PM ET
3060 - Matched Pair Analysis of Locally Advanced Pancreatic Cancer Patients Treated with Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy (MAPLAP)
3061 - Ablative MRI-Guided Radiation for GI Neuroendocrine Tumors: Assessment of Local Control and Toxicity
Location: Hall C
Presenter: John Peterson, MD – H. Lee Moffitt Cancer Center and Research Institute
12:45 PM - 2:00 PM ET
3062 - Toward Non-Operative Management of Locally Advanced Rectal Cancer Patients Undergoing Short Course Chemoradiotherapy: Early Response Prediction via Longitudinal Apparent Diffusion Coefficient
3064 - First Exploration of the Characterization and Dosimetric Predictors for Absolute Lymphocyte Count Changes during nCRT with or without Pembrolizumab for Esophageal Squamous Cell Carcinoma: An Analysis
Location: Hall C
Presenter: Wei-Xiang Qi, MD, RT – Ruijin Hospital, Shanghai Jiaotong University School of Medicine
12:45 PM - 2:00 PM ET
3065 - Frailty Index and Early Mortality in Older Adults with Gastrointestinal Malignancies Treated with Radiation
3066 - Safety and Efficacy of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma in Patients with Advanced Cirrhosis Awaiting Liver Transplantation: An ROI-funded Prospective Pilot Study
3067 - Alliance A022101/NRG-GI009: A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer - Evaluating Radiation, Ablation and Surgery
Location: Hall C
Presenter: Paul Romesser, MD – Memorial Sloan Kettering Cancer Center
12:45 PM - 2:00 PM ET
3068 - Radiosensitization Adding Hydrogen Peroxide to Neoadjuvant Chemoradiotherapy of Rectal Cancer
3069 - Sinonasal Melanoma Outcomes after Neoadjuvant Immunotherapy
Location: Hall C
Presenter: Aya Salem, MD – MD Anderson Cancer Center
12:45 PM - 2:00 PM ET
3070 - Efficacy and Safety of Toripalimab Combined with Radiotherapy and S-1 Followed by Adjuvant Toripalimab Maintenance Therapy for Older Patients with Esophageal Cancer
Location: Hall C
Presenter: Wen Bin Shen, MD – The Fourth Hospital of Hebei Medical University
12:45 PM - 2:00 PM ET
3071 - Outcomes of Salvage Ablative Radiotherapy on Hepatocellular Carcinoma for Isolated Location Recurrence in Regional Lymph Nodes and Adrenal Glands
Location: Hall C
Presenter: Kristin Hsieh, MD – Icahn School of Medicine at Mount Sinai
12:45 PM - 2:00 PM ET
3072 - A Prospective Pilot Study of Cardiac MRI (cMRI) for Evaluation of Early Cardiac Toxicity in Patients Receiving Neoadjuvant Chemoradiotherapy (nCRT) for Esophageal Cancer
3075 - Locally Advanced Rectal Cancer: Can Total Mesorectal Irradiation Decrease Pelvic Toxicity?
Location: Hall C
Presenter: Pranit Singh, BS – USF Health Morsani College of Medicine
12:45 PM - 2:00 PM ET
3076 - EMERALD-Y90: A Phase 2 Study to Evaluate Transarterial Radioembolization Followed by Durvalumab and Bevacizumab for the Treatment of Unresectable Hepatocellular Carcinoma Eligible for Embolization
3077 - Enhancing Radiotherapy Response via Intratumoral Injection of the TLR9 Agonist CpG to Stimulate CD8 T Cells in an Autochthonous Mouse Model of Sarcoma
3080 - Outcomes and Predictors of Toxicity after Stereotactic Body Radiotherapy for Child-Pugh B or C Hepatocellular Carcinoma in a Fiducial-Less Setting
3086 - LASSO Regression to Identify Significant Patient Factors and Develop Survival Model in Patients with Cutaneous Melanoma: Results of 20,981 Cases from SEER Database
3087 - Multi-Omics Sequencing Unveils Tumor Microenvironment Remodeling Induced by Combined Radiotherapy and Immunotherapy in Microsatellite-Stable Locally Advanced Rectal Cancer
3088 - Pathological Response and Survival Outcome after Neoadjuvant Chemoradiotherapy vs. Immunochemotherapy for Patients with Locally Advanced Esophageal Squamous Cell Carcinoma
3089 - Efficacy and Safety of Radiotherapy Combined with Chemoimmunotherapy vs. Chemoimmunotherapy Alone as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma with Oligorecurrence
3090 - Radiotherapy Combined with Chemoimmunotherapy vs. Chemoimmunotherapy Alone As First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma with Oligometastasis at Initial Diagnosis
3092 - Phase II Study of Sintilimab Combined with Chemotherapy and Sequential Radiotherapy in First-Line Treatment of Oligometastatic Esophageal Cancer
3094 - Tislelizumab plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients after Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Stu
3095 - Evaluation of Breath-Hold Techniques for Pancreatic Cancer Stereotactic Ablative Radiotherapy via Intra-Fractional Kilo-Voltage Imaging and Fiducial Tracking
Location: Hall C
Presenter: Siqiu Wang, PhD – University of Texas Southwestern Medical Center
12:45 PM - 2:00 PM ET
3096 - Evaluating the Long-term Outcomes of Preoperative Radiation and Conservative Surgery in Extremity and Trunk Soft Tissue Sarcoma
3097 - Preoperative Short-Course Radiotherapy Combined with Chemotherapy and Tislelizumab for Locally Advanced Middle-Low Rectal Cancer: A Randomized Phase I/II Clinical Study
3100 - Sarcopenia as an Independent Prognostic Factor for Neoadjuvant Chemoradiation Efficacy in Locally Advanced Rectal Cancer: A Retrospective Analysis
3104 - Comparison of Anlotinib and S-1 Combined with Radiotherapy in the Treatment of Elderly Patients with Inoperable Esophageal Squamous Cell Cancer: An Open-Label, Phase 2, Randomized Controlled Trial
3105 - Prognostic Value of Sarcopenia and Inflammatory Indices Synergy in Patients with Esophageal Squamous Cell Carcinoma Undergoing Chemoradiotherapy
3106 - A Single Arm Phase II Study of Neoadjuvant Chemoradiotherapy and AK104 in pMMR/MSS Locally Advanced Rectal Cancer with Positive PD-L1 Expression
3107 - A Real-World Long-Term Outcome of Intensity-Modulated Radiation Therapy plus Concurrent Chemotherapy in Locally Advanced Anal Squamous Cell Carcinoma
Location: Hall C
Presenter: Tongzhen Xu, MD – Chinese Academy of Medical Science
12:45 PM - 2:00 PM ET
3108 - The Japanese Nationwide Prospective Cohort Data of Proton Beam Therapy for Liver Oligometastasis in Pancreatic Cancer Patients
3109 - Survival and Follow-Up Strategies of Watch-and-Wait Patients with a Clinical Complete Response after Selective High-Dose Neoadjuvant Radiotherapy in Rectal Cancer
Location: Hall C
Presenter: Chen Yang, MD – Sun Yat-Sen University Cancer Center
12:45 PM - 2:00 PM ET
3110 - Neoadjuvant Chemoradiotherapy plus Sequential Tislelizumab Followed by Surgery for Esophageal Carcinoma (CRISEC study): A Prospective, Single-Arm, Phase II Trial
Location: Hall C
Presenter: Jinsong Yang, MD – Cancer Institute and Hospital Chinese Acedemy of Medical Sciences
12:45 PM - 2:00 PM ET
3111 - Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) for the Treatment of Gastrointestinal Cancers
3115 - Final Results of the First Clinical Trial of a Novel Unidirectional Permanent Device for Intraoperative Brachytherapy
Location: Hall C
Presenter: Irini Youssef, MD – Memorial Sloan Kettering Cancer Center
12:45 PM - 2:00 PM ET
3116 - "Pacific" Modality in Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis of a Real-World Multicenter Study
3118 - President: A Randomised Phase III Trial of Preoperative Chemoradiation Versus Post Operative Chemoradiation for Locally Advanced Potential Resectable Gastric Cancer.
3121 - Pathological Response and Locoregional Control in Gastric Cancer Patients after Preoperative Chemoradiation Versus Preoperative Chemotherapy: Data from the Neo-Crag Clinical Trial
3122 - Cellular Senescence Index Predicts Radiotherapy Response and Outcomes in Esophagus Cancer Patients
Location: Hall C
Presenter: Zengfu Zhang, MD – Shandong Cancer Hospital and Institute
12:45 PM - 2:00 PM ET
3123 - Improving Resectability and Prognosis in Initially Unresectable Locally Advanced Colon Cancer through Neoadjuvant Chemoradiotherapy: A Single-Center Retrospective Study
3125 - Efficacy and Safety of the Combination of Tislelizumab with Chemoradiotherapy in Oligorecurrence Esophageal Squamous Cell Carcinoma: A Prospective Phase II Study
Location: Hall C
Presenter: ziyu zheng, MB – National Cancer Center/National Clinical Research Center for Cancer Cancer Hospital, CAMS & PUMC
12:45 PM - 2:00 PM ET
3126 - Efficacy and Safety of PD-1 Inhibitors and Targeted Drugs Combined with Radiotherapy in First-Line Treatment of Oligometastatic Hepatocellular Carcinoma
3135 - Node Positive Prostate Cancer Treated with Brachytherapy Boost
Location: Hall C
Presenter: Rahul Barve, MD – Memorial Sloan Kettering Cancer Center
2:30 PM - 3:45 PM ET
3136 - Patient Reported Quality of Life (QOL) Outcomes for Intermediate-High Risk-Very High Risk Prostate Cancers Treated By SBRT and Androgen Deprivation Therapy (ADT)
3137 - Association of Tumor Volume and Radiographic T-Stage for Patients with Localized Prostate Cancer Treated with Radiation or Radical Prostatectomy
3138 - Daily Adaptive Post-Prostatectomy Radiation Therapy (DAPPER): Initial Treatment Planning and Delivery Outcomes Using CT-Based Online Adaptive Radiation Therapy
Location: Hall C
Presenter: Alexandra Bennett, MD – Mayo Clinic College of Medicine and Science Rochester
2:30 PM - 3:45 PM ET
3139 - Effectiveness of an Iodinated Perirectal Hydrogel Spacer for Prostate Cancer Treated with Stereotactic Body Radiotherapy (SBRT): A Prospective, Multi-Center, Randomized Trial ("SABRE")
3140 - Development of a Consensus Checklist for Systematic Radiation Treatment Plan Review
Location: Hall C
Presenter: Graham Boyd, MD – Dana-Farber/Brigham and Women's Cancer Center
2:30 PM - 3:45 PM ET
3141 - MRI-Guided Adaptive SBRT for Kidney and Adrenal Gland Tumors: An Analysis of the Intra-Fractional Tumor Motion and Inter-Fractional Dosimetric Impact
Location: Hall C
Presenter: Lingling Cai, MB – Sun Yat-Sen University Cancer Center
2:30 PM - 3:45 PM ET
3142 - 3D-Printed Seed Placement Template for 125I Seed Plaque Assembly with Custom Eye Plaques
Location: Hall C
Presenter: Kaitlyn Calabresi, BS – Louisiana State University Health Sciences Center
2:30 PM - 3:45 PM ET
3143 - Geographical Comparison of Medicare & Medicaid Services (CMS) Standard Charges for Complex Proton Therapy
Location: Hall C
Presenter: Kasey Cargill, PhD – University of Pittsburgh School of Medicine
2:30 PM - 3:45 PM ET
3144 - Severe Genitourinary Events Following Definitive Radiation Therapy for Patients with Locally Advanced and Metastatic Bladder Cancer: A Single Institution Experience
3145 - An LLM-Based Framework for Zero-Shot De-Identifying Flexible Text Data in Protected Health Information Enabling Potential Risk-Informed Patient Safety
3147 - Clinical Efficacy and Adverse Effects of Adjuvant Radiotherapy Following Surgery in High-Risk Renal Cell Carcinoma(RCC) Patients - A Single Center Experience
Location: Hall C
Presenter: Jiayan Chen, MD – Peking University First Hospital
2:30 PM - 3:45 PM ET
3148 - Racial Variation in the Advanced Prostate Cancer Genome
3155 - Evaluation of Clinical and Educational Impact of Head and Neck-Specific Chart Rounds in a High-Volume Multi-Center Integrated Health Care System
Location: Hall C
Presenter: Fara Dayani, MD, MS – Kaiser Permanente Los Angeles Medical Center
2:30 PM - 3:45 PM ET
3156 - Stereotactic Ablative Radiotherapy for Renal Cell Carcinomas - An Experience from a Single Center
3160 - International Harmonization of Technical Approaches to Kidney SABR - An International Radiosurgery Consortium of the Kidney (IROCK) Contouring Project
3163 - Risk of Death in Octogenarians with Intermediate Risk Prostate Cancer Who Are Treated with Radiation Therapy (RT) Plus Androgen Deprivation Therapy (ADT) Versus Radiation Alone, an NCDB Analysis
3164 - Apparent Diffusion Coefficient as an Early Prognostic Factor of Response to Treatment with Androgen Deprivation Therapy and Radiotherapy in Patients with Prostate Cancer
3169 - Real-World Medical Device Reports of PEG Hydrogel Spacers: Analysis of the FDA Manufacturer and User Facility Device Experience (MAUDE) Database
3170 - Early Results from a Prospective Trial Testing Stereotactic Salvage Radiotherapy for Macroscopic Prostate Bed Recurrence after Prostatectomy-STARR(NCT05455736)
3174 - Disease Site Specific Peer Review Highlights the Need for Prospective Contour Review for Head and Neck Treatment Planning
Location: Hall C
Presenter: Beth Ghavidel, MS – Winship at Emory University Hospital Midtown
2:30 PM - 3:45 PM ET
3175 - Enhancing Workflow Efficiency for Managing Patients with Cardiac Implantable Electronic Devices in Radiation Oncology: A Lean Approach
Location: Hall C
Presenter: Beth Ghavidel, MS – Winship at Emory University Hospital Midtown
2:30 PM - 3:45 PM ET
3176 - Pattern of Failure Following Salvage Radiation Therapy after Prostatectomy
Location: Hall C
Presenter: Lucia Goanta, MD – Regina Elena National Cancer Institute
2:30 PM - 3:45 PM ET
3177 - International Prostate Symptom Score Outcomes of Five Different Treatment Paradigms for Localized Prostate Cancer: A Single-Institution Experience
3178 - The Effect of Age on Clinicopathological Features and Treatment Outcomes of Patients Receiving Definitive Radiotherapy for Localized Prostate Cancer
3179 - Prostate-Specific Membrane Antigen-Directed Focal Stereotactic Radiation Therapy in Two Fractions for Locally Recurrent Prostate Cancer after Definitive Radiation Therapy
3180 - Effect of Ethnic Concordance in Post-Treatment Follow-Up and Surveillance of Korean American Breast Cancer Patients Treated with Adjuvant Radiotherapy
Location: Hall C
Presenter: Hye Ri Han, MD, MS – University of Southern California/Los Angeles General Medical Center
2:30 PM - 3:45 PM ET
3181 - Clinical Workflow Evaluation of High-Performance Imaging on a C-Arm Linear Accelerator
3184 - A Phase Il Clinical Study of Axitinib and Toripalimab Combined with Stereotactic Radiation (SBRT) for Metastatic Renal Cell Carcinoma (mRCC) after Oligoprogression from First-Line Anti-Angiogenic Ther
Location: Hall C
Presenter: Lingling Cai, MB – Sun Yat-Sen University Cancer Center
2:30 PM - 3:45 PM ET
3184 - A Phase Il Clinical Study of Axitinib and Toripalimab Combined with Stereotactic Radiation (SBRT) for Metastatic Renal Cell Carcinoma (mRCC) after Oligoprogression from First-Line Anti-Angiogenic Ther
Location: Hall C
Presenter: Liru He, PhD – Sun Yat-Sen University Cancer Center
2:30 PM - 3:45 PM ET
3185 - Rectal Wall Infiltration with Hyaluronic Acid Based Rectal Spacer and Its Reversal
3187 - The Performance of Multiparametric MRI in Identification of Intraprostatic Tumor Deposits after Local Prostate Radiation Therapy
Location: Hall C
Presenter: R. Hsi, MD – University of Washington-Fred Hutchinson Cancer Center
2:30 PM - 3:45 PM ET
3188 - Mid-Term Analysis of the Combination Therapy of Axitinib, Toripalimab, and Stereotactic Ablative Body Radiotherapy (SABR) in the Treatment of Recurrent Metastatic Renal Cell Carcinoma
Location: Hall C
Presenter: Ke Hu, MD – Peking University First Hospital
2:30 PM - 3:45 PM ET
3189 - Outcomes of Primary Tumor Stereotactic Ablative Body Radiotherapy for Localized and Metastatic Renal Cell Carcinoma
3197 - Radiation Therapy for Prostate Cancer: Baseline Platelet Count and Anti-Platelet and Anticoagulant Use Are Associated with Disease Outcomes in a Cohort of 1000 Men
3197 - Radiation Therapy for Prostate Cancer: Baseline Platelet Count and Anti-Platelet and Anticoagulant Use Are Associated with Disease Outcomes in a Cohort of 1000 Men
3205 - Psmaddition: Phase 3 Trial of [177lu]Lu-PSMA-617 Plus Standard of Care (SoC) vs. Soc Alone in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Location: Hall C
Presenter: Hyun Kim, MD – Washington University School of Medicine in St. Louis
2:30 PM - 3:45 PM ET
3206 - Context-Dependent Impact of Tumor-Infiltrating B Cells in High-Risk Prostate Cancer and Head and Neck Cancer
Location: Hall C
Presenter: Sangwoo Kim, MD – University of California, San Diego
2:30 PM - 3:45 PM ET
3207 - Inter- and Intra-Observer Variability in Catheter Localization in High-Dose-Rate Brachytherapy for Prostate Cancer with Stepping Transverse and Twister Sagittal Volume Scanning
3210 - 18F-Flotufolastat Detection Rates in the Pelvis Region for Patients with Prostate Cancer Recurrence after Radical Prostatectomy and PSA Levels <1 ng/mL: Data from the Phase 3 SPOTLIGHT S
3211 - Association of MRI Capsular Involvement and Extraprostatic Extension on Metastasis Free and Overall Survival in Localized Prostate Cancer Treated with Radiation
3215 - A Secondary Analysis of Radiotherapy Oncology Group (RTOG/NRG) Trials 9202, 9413, and 9910: Unknown Causes of Death and Their Impact on Prostate Cancer Specific Mortality Estimates
Location: Hall C
Presenter: Joan Lee, MD – University Hospitals Cleveland Medical Center
2:30 PM - 3:45 PM ET
3216 - Feasibility of PSMA PET-Assisted MR-Guided Radiotherapy for Prostate Cancer Patients Treated with Curative Aim
Location: Hall C
Presenter: Joon-gyo Lee, MD – Gachon University Gil Medical Center
2:30 PM - 3:45 PM ET
3217 - Prognostic Value of Central Gland Volume on MRI for Biochemical Recurrence after Prostate Cancer Radiotherapy
Location: Hall C
Presenter: Joseph Lee, MD, PhD – Corewell Health William Beaumont University Hospital
2:30 PM - 3:45 PM ET
3218 - Decoding Cancer Radiotherapy Discontinuation: A Comprehensive Analysis
3221 - The Effectiveness of Radiotherapy for Upper Tract Urothelial Carcinoma (UTUC) with Lymph Node Metastasis and Optimal Target Delineation for Clinical Target Volume
Location: Hall C
Presenter: Xiaoying Li, MD – Peking University First Hospital
2:30 PM - 3:45 PM ET
3222 - Impact of Hyaluronic Acid (HA) Rectal Spacer Quality Score (SQS) and Fischer-Valuck (FV) Spacer Symmetry Score on Rectal Dosimetry and Acute and Late Gastrointestinal (GI) Toxicity Outcomes - An Austr
3225 - Exploring Gene Expression and Pathway Analysis in Localized Prostate Cancer: Insights from a Retrospective Cohort Study with a Focus on Hypoxia and Angiogenic Biomarkers Post-EBRT and HDR-BTb
3227 - A Prospective Cohort Study Assessing Patient Reported Outcomes after Post-Prostatectomy Radiation Therapy: Longer-Term Follow-Up through 5 Years
3228 - Impact of Posterior PTV Margin on the Treatment Efficiency and Adverse Effects of Radical Radiotherapy for Prostate Cancer Patients
Location: Hall C
Presenter: Lin Ma, MD – Peking University First Hospital
2:30 PM - 3:45 PM ET
3229 - A Prospective Cohort Study Evaluating the Efficacy and Safety of Adjuvant Chemotherapy in High-Risk Non-Metastatic Prostate Cancer Patients with High Gleason Scores
Location: Hall C
Presenter: Ming-Wei Ma, MD – Peking University First Hospital
2:30 PM - 3:45 PM ET
3230 - Patterns of Care and Associated Socioeconomic Determinants of Health in the Definitive Treatment of Localized Muscle-Invasive Bladder Cancer Patients
Location: Hall C
Presenter: Megan Mai, MPH – Texas Tech University Health Science Center
3236 - Hyaluronic Acid Rectal Spacer in Locally Recurrent Prostate Cancer with Prior Radiation Receiving SBRT: A Report on Feasibility, Safety and Toxicity
3243 - Testosterone Recovery and Associated Impact on Patient-Reported Health-Related Quality of Life (HRQoL) after Treatment with 6 Months of GnRH Agonist with or without Abiraterone Acetate plus Prednisone
3244 - A Randomized Phase II Trial of High Dose-Rate (HDR) and Low Dose-Rate (LDR) Brachytherapy as Monotherapy in Localized Prostate Cancer: Analysis of Initial Arms of Canadian Cancer Trials Group PR19 (NC
3245 - Correlation of Circulating Tumor DNA (ctDNA) Dynamics with Clinical Response in Muscle-Invasive Bladder Cancer (MIBC) Patients Undergoing Trimodality Therapy (TMT)
Location: Hall C
Presenter: Kent Mouw, MD, PhD – Dana-Farber/Brigham and Women's Cancer Center
2:30 PM - 3:45 PM ET
3246 - Customized Electronic Quality Checklists to Reduce Errors and Improve Radiotherapy Workflow
3249 - Quality of Life and Weight Variation during Androgen Deprivation Therapy in Patients with High-Risk Prostate Cancer: Long-Term Data from a Phase III Trial
3250 - Phase 2 Prospective Trial of Re-Treatment with 177lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration Resistant Prostate Cancer (RE-LuPSMA): Study Protocol
3252 - Comparison of Decipher vs. Oncotype (GPS) Genomic Profiling Scores in NCCN Intermediate Risk Prostate Cancer Patients
Location: Hall C
Presenter: Edward Obedian, MD – The Cancer Institute at St. Francis Hospital
2:30 PM - 3:45 PM ET
3253 - The Safety and Efficacy of Lutetium-177-PSMA-617 Therapy for Metastatic CRPC in a Real World Community Cancer Center
Location: Hall C
Presenter: Edward Obedian, MD – The Cancer Institute at St. Francis Hospital
2:30 PM - 3:45 PM ET
3254 - Investigating the Machine Learning-Derived Nomogram Models and Biomarkers for Side-Specific Prediction of Extraprostatic Extension of Prostate Cancer - Preliminary Results
3256 - Treatment Outcomes of External Beam Radiotherapy with or without Focal Boost to Intraprostatic Lesions in Patients with Localized Prostate Cancer
3258 - Study on the Focal Boost to the Dominant Intraprostatic Lesions Using Proton Therapy in High-Risk Prostate Cancer Patients with Pelvic Lymph Node Irradiation: Assessing Toxicity Using the Accumulated
3264 - Ultra-Short-Course Hormone Therapy for Intermediate Risk Prostate Cancer Treated with Definitive Radiotherapy: Retrospective Analysis of a National Healthcare System
3275 - Automated Template-Based Planning and Prostate Stereotactic Body Radiotherapy without Real-Time Seed-Tracking: A Regional Service Experience
Location: Hall C
Presenter: Amie Ross, RT – Mid North Coast Cancer Institute (MNCCI) Coffs Harbour
2:30 PM - 3:45 PM ET
3277 - Association of Absolute Amount of Pattern 4 Disease on Prostate Biopsy with Oncologic Outcomes in Intermediate-Risk Prostate Cancer: A Systematic Review
3279 - Safety Profile of High-Dose Intensity Modulated Radiotherapy in Prostate Cancer: Preliminary Findings from the JROSG 17-5 Multicenter Prospective Observational Study in Japan
3287 - Comparison of Urethra Morphology on CT with Urinary Catheter and MRI without Urinary Catheter after Low Dose Rate Prostate Cancer Brachytherapy
Location: Hall C
Presenter: Ingrid Sidibe, MD – CHU de Quebec - Universite Laval - Centre integre de cancerologie
2:30 PM - 3:45 PM ET
3288 - Moderately Hypofractionated Proton Therapy with or without Implantable Spacer in Patients with Localized Prostate Cancer
Location: Hall C
Presenter: Soborun Kaviraj, MD – Universitatsklinikum Dresden Klinik f Strahlentherapie und Radioonkologie
2:30 PM - 3:45 PM ET
3289 - Veterans Affairs seamless phase II/III randomized trial of STAndard systemic theRapy with or without PET-directed local therapy for Oligometastatic pRosTate cancer (VA STARPORT)
3298 - Predicting Chemoradiotherapy Induced Cardiotoxicity in Breast Cancer Patients Using Machine Learning Based Clinical, Imaging and Dosimetric Radiomics Features
Location: Hall C
Presenter: Beth Ghavidel, MS – Winship at Emory University Hospital Midtown
2:30 PM - 3:45 PM ET
3299 - Organ at Risk Dose Constraints in Conventionally Fractionated Pelvic Radiation Therapy: A Systematic Review of Clinical Trials
3301 - A Phase 4 Open-Label Multicenter Study of Piflufolastat F 18 PET/CT or PET/MRI in Men with Newly Diagnosed Favorable Intermediate Risk Prostate Cancer: MIRROR
3305 - Physician Assessment and Clinical Evaluation of the Suitability of Deep Learning Based Auto Segmentation Contours for Organs at Risk Delineation in Radiation Oncology
Location: Hall C
Presenter: Sarah Way, MS – Minneapolis Radiation Oncology PA
2:30 PM - 3:45 PM ET
3306 - Assessing Bilateral Neurovascular Bundles Function with Pulsed Wave Doppler Ultrasound: Implications for Reducing Erectile Dysfunction Following Prostate Radiotherapy
Location: Hall C
Presenter: Tian Liu, PhD – Icahn School of Medicine at Mount Sinai
2:30 PM - 3:45 PM ET
3307 - Efficacy of an Adaptive Plan Quality Predictor for Decision Support in Online MR-Guided Adaptive Radiotherapy for Prostate Stereotactic Ablative Radiotherapy
Location: Hall C
Presenter: Siqiu Wang, PhD – University of Texas Southwestern Medical Center
2:30 PM - 3:45 PM ET
3308 - Daily Online Adaptive Radiotherapy for Rectal Cancer Utilizing CT-Linac: Assessing Feasibility, Toxicities and Optimal Margins
3309 - Factors Associated with Completion of Treatment Course with Lutetium-177 Vipivotide Tetraxetan in Men with Metastatic Castration-Resistant Prostate Cancer at a Single Institution
Location: Hall C
Presenter: Peter Whatts, MD – Detroit Medical Center/Wayne State University
2:30 PM - 3:45 PM ET
3310 - Characterizing Failure after Trimodality Therapy in Bladder Cancer: A Retrospective Analysis of Clinical, Spatial and Dosimetric Factors
3311 - Baseline Characteristics of Patients Enrolled on the Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL) Trial Comparing Proton Therapy vs. IMRT for Low or Intermediate R
3313 - Dosimetric Study of Dose De-Escalation Using MRI-Guidance in Low and Intermediate Risk Prostate Cancer Patients with Pd-103 Low Dose Rate Brachytherapy
3317 - Calculation of Dose Perturbations Caused by 2 mm of Intraprostatic Calcification for Permanent Prostate Seed Implant Using Pd103 in Excel/Python
3319 - Caring for the Carers: Factors Associated with Perceived Burden among Caregivers of Filipino Cancer Patients Undergoing Radiation Therapy in Two Tertiary Care Hospitals in the Philippines
3324 - A Novel Six-Zone Method to Guide Delineation of Clinical Target Volume (CTV) for Postoperative Radiotherapy of Prostate Cancer, Based on the Distribution of Prostate Bed Recurrence by PSMA PET
3326 - Impact of CT Online Adaptive Radiotherapy on Acute Toxicity in Patients Undergoing Prostate Radiotherapy
Location: Hall C
Presenter: Lin Zhu, MD, PhD – Harvard Radiation Oncology Program
2:30 PM - 3:45 PM ET
3327 - Analysis of the Treatment Planning Quality Assurance Reports for Intensity Modulated Proton Therapy at an Established Proton Center
Location: Hall C
Presenter: Mingyao Zhu, PhD – Emory University School of Medicine
2:30 PM - 3:45 PM ET
3328 - Optimizing Rectal Dose and Minimizing Toxicity in Prostate Radiotherapy in a Randomized Pivotal Trial: Assessment of Rectal Spacer Placement Effect on Rectal Dosimetry and Toxicity
3333 - Predicting Absolute Risk of First Relapse in Classical Hodgkin Lymphoma by Incorporating Contemporary Treatment Effects
Location: Hall C
Presenter: Berthe Aleman, MD, PhD – Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL)
4:00 PM - 5:00 PM ET
3334 - Artificial Intelligence for Identification of Radiation-Related Toxicities from the Electronic Health Records of Patients with Head and Neck Cancer
3335 - Genome-Wide Cell-Free DNA Fragmentation Analyses for Early, Non-Invasive Detection of Treatment Response to Standard of Care Adjuvant Radiation Treatment in High-Grade Gliomas
3336 - Development of Machine Learning Algorithms from Computed Tomography Images to Predict Catastrophic Airway Events in Patients with Cancers in the Aerodigestive Tract
3338 - Left Ventricular Sphericity as a Radiomic Predictor of Cardiac Outcomes after Thoracic Radiotherapy for Lung Cancer
Location: Hall C
Presenter: Mina Bakhtiar, MD – Mass General Brigham/Massachusetts General Hospital/Harvard Med School
4:00 PM - 5:00 PM ET
3339 - Validation of Multi-Modal Artificial Intelligence Biomarker for Predicting Biochemical Recurrence in Patients with Prostate Cancer Undergoing Prostatectomy
Presenter: Arnold Pompos, PhD – University of Texas Southwestern Medical Center
4:00 PM - 5:00 PM ET
3352 - Multi-Channel 3D Convolutional Neural Network to Predict Grade 2 Xerostomia Following Definitive Radiation for Head and Neck Squamous Cell Carcinoma
3353 - Impact of Deep Learning Auto Segmentation Accuracy on Duodenal Dose-Volume Parameters for Pancreas SBRT Patients Treated with MR-Guided Online Adaptive Radiotherapy
3355 - Radiation Therapy (RT) in a New Era of Multiple Myeloma (MM) Therapy: Trends of Engagement and Radiologic, Biochemical, and Cytogenetic Correlates of Outcomes and Response
3359 - A Novel Interactive Online Visualizer for Clinical Trial Data
Location: Hall C
Presenter: Michelle Ann Eala, MD – UCLA David Geffen School of Medicine/UCLA Medical Center
4:00 PM - 5:00 PM ET
3360 - Proton Pencil Beam Scanning Facilitates Safe Treatment of Extended Radiation Targets for Hodgkin Lymphoma: A Report from the Proton Collaborative Group Registry
3372 - A CD8 T Cell Radiomics Score Correlates with Local Failure in Patients Undergoing Combined SBRT and Immune Checkpoint Inhibition in a Pooled Analysis of Three Phase I Trials
3373 - Using High-Repeatable Radiomic Features Improves the Cross-Institutional Generalization of Prognostic Model in Esophageal Cancer Receiving Definitive Chemoradiotherapy
Location: Hall C
Presenter: Jie Gong, PhD – Life Sciences Research Center, School of Life Sciences and Technology, Xidian University,
4:00 PM - 5:00 PM ET
3374 - Pathology AI for Risk Stratification (PAIRS): Predicting Adverse Pathological Features in Post-Operative Head and Neck Cancer with Large Language Models
3377 - Spatially Fractionated Radiation Therapy (SFRT) Based on Multimodal Imaging: A Promising Salvage Treatment Strategy for Metastatic and Refractory Cancer Patients
Location: Hall C
Presenter: Y.X. Guo, MD – Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
4:00 PM - 5:00 PM ET
3378 - The Impact of Radiotherapy on Survival Outcomes in Plasmablastic Lymphoma
3386 - Utility of Analytics in a Large Community-Based Radiation Oncology Network: Consolidation and Standardization of Clinical, Operational and Quality Metrics
3389 - Improving Intestinal Crypt Detection in Deep Learning Models with Reinhard Method-Based Stain Color Normalization for Evaluating Normal Tissue Radiation Response
Location: Hall C
Presenter: Matthew Kim, BS – Stanford University School of Medicine
4:00 PM - 5:00 PM ET
3390 - Treatment of Patients with Gastric Extranodal Marginal Zone Lymphomas (MZL) Using CBCT-based Adaptive Radiotherapy (ART) to Reduce Margins
3391 - Multi-Omics Models can Predict Prostate Specific Membrane Antigen Avidity for Computed Tomography Lesions in Oligo-Metastatic Castration Sensitive Prostate Cancer
Location: Hall C
Presenter: Ritesh Kumar, MD – Rutgers Cancer Institute of New Jersey
4:00 PM - 5:00 PM ET
3392 - Trends in Radiation Fractionation for Early-Stage Follicular or Marginal Zone Lymphoma
Location: Hall C
Presenter: Raymond Zou, BA – City of Hope National Medical Center
4:00 PM - 5:00 PM ET
3393 - Optimizing Radiation Oncology: Integrating Clinical Decision Support and Automated Treatment Planning for Enhanced Quality, Consistency and Efficiency
3394 - Ultra-Low-Dose Adaptive Radiotherapy and Single-Agent Rituximab for Indolent Non-Hodgkin Lymphomas: Where Less is More in Combined Modality Therapy
3399 - Value of Peritumoral Radiomics in Predicting Local Recurrence-Free Survival in Esophageal Squamous Cell Carcinoma Receiving Definitive (Chemo)Radiotherapy
3404 - Deep Learning-Based Fully Automated Detection and Segmentation of Lymph Nodes on Computed Tomography for Head and Neck Cancer: A Multi-Center Study
3405 - Evaluation of Deep Learning-Based Abdominal Organ Segmentation Models: Assessing Robustness across Non-Surgery to Organ Resection Surgery Patients
3406 - Deep Learning with Biopsy Whole Slide Images for Predicting Pathological Complete Response to Neoadjuvant Immunochemotherapy in Esophageal Squamous Cell Carcinoma
3409 - Multimodality Deep Learning Radiomics Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy
Location: Hall C
Presenter: Yunsong Liu, MD – National Cancer Center/National Clinical Research Center for Cancer Cancer Hospital, CAMS & PUMC
4:00 PM - 5:00 PM ET
3410 - Tumor Response to Induction Chemotherapy Followed by Radiotherapy, Chemotherapy Intensity, and Patients with Early-Stage Extranodal Natural Killer/T Cell Lymphoma
Location: Hall C
Presenter: Huang Luo, MD – Chongqing University Cancer Hospital
4:00 PM - 5:00 PM ET
3411 - Construction and Selection of the Automatic Segmentation Tools for High-Risk Clinical Tumor Volume in Brachytherapy for Cervical Cancer Based on Deep Learning
Location: Hall C
Presenter: Chenying Ma, MD, PhD – The First Affiliated Hospital of Soochow University
4:00 PM - 5:00 PM ET
3412 - The Directive Application: Enhancing Clinical Workflow and Transforming Oncology Care with Centralized Data Management
3415 - Cancer Treatment Information Differences by Bilingual Prompting in Large Language Model Chatbots
Location: Hall C
Presenter: Javier Mora, MD – Harvard Radiation Oncology Program
4:00 PM - 5:00 PM ET
3416 - Multiomic Based Bayesian Network Toxicity Modeling for Simultaneous Prediction of Multiple Toxicity Outcomes in NSCLC
Location: Hall C
Presenter: Saurabh Nair, MSc – The university of Texas M. D. Anderson Cancer Center
4:00 PM - 5:00 PM ET
3417 - Patterns of CNS Failures in Relapse/Refractory Large B-Cell Lymphoma (LBCL) Patients with Secondary CNS Disease Following Chimeric Antigen Receptor T-Cell (CAR T) Therapy
3420 - A Machine-Learning Model to Predict Axillary Node Positivity from Clinical Characteristics and Large-Scale DNA Organization Features in Breast Cancer Biopsy Specimens
3429 - Balancing Prevalence of Contrast and Non-Contrast Computed Tomography Examples in a Limited Set and Training Transformer-Based Great Vessel Segmentation
Location: Hall C
Presenter: Chloe Choi, MS – Memorial Sloan Kettering Cancer Center
4:00 PM - 5:00 PM ET
3430 - Quantitative and Qualitative Evaluation of an Automatic and Manual GTV Contouring Tool in Pre-Radiotherapy MRI in Glioblastoma Treatment
3434 - Independent Validation and Performance Comparison of Published Radiation Pneumonitis NTCP Models for IMRT, Immunotherapy and Proton Therapy Cohorts
Location: Hall C
Presenter: Ramon Salazar, PhD – University of Texas MD Anderson Cancer Center
4:00 PM - 5:00 PM ET
3435 - Adaptive Radiation Fractionation in Head and Neck Cancer through Modeling Tumor Volume Dynamics
3448 - Radiation to Sites of Skeletal Involvement in Large B-Cell Lymphoma: Trends and Impact on Survival
Location: Hall C
Presenter: Kim Vo, DO, MS, BS – City of Hope Comprehensive Cancer Center
4:00 PM - 5:00 PM ET
3449 - Analysis of Dual-Energy CT (DECT) Parameters in Patients with Stage I Non-Small Cell Lung Cancer Treated with Stereotactic Ablative Body Radiation (SABR) in a Prospective Study
3453 - Patterns of Locoregional Recurrence and Prognosis in Early-Stage Natural Killer/T-Cell Lymphoma after Chemotherapy with Sandwiched Radiotherapy: A Post Hoc Analysis of a Randomized Controlled Clinical
Location: Hall C
Presenter: Shubei Wang, MD – Ruijin Hospital, Shanghai Jiaotong University School of Medicine
4:00 PM - 5:00 PM ET
3454 - Treatment and Survival in Early-Stage MALT Lymphoma: A Retrospective Study of Outcomes at a Single Institution
Location: Hall C
Presenter: Xinyue Wang, MD – Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
4:00 PM - 5:00 PM ET
3455 - MRI-Guided Real-Time Adaptive Radiotherapy for Liver with Deep Learning